TRCT
FHTX icon

Tower Research Capital (TRC)’s Foghorn Therapeutics FHTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8K Buy
3,295
+1,222
+59% +$6.71K ﹤0.01% 3653
2025
Q4 		$11.2K Sell
2,073
-431
-17% -$1.95K ﹤0.01% 3635
2025
Q3 		$12.2K Sell
2,504
-6,709
-73% -$35.6K ﹤0.01% 3805
2025
Q2 		$43.3K Buy
9,213
+5,323
+137% +$22.2K ﹤0.01% 3094
2025
Q1 		$14.2K Buy
3,890
+1,786
+85% +$8.14K ﹤0.01% 3308
2024
Q4 		$9.93K Buy
2,104
+683
+48% +$4.98K ﹤0.01% 3857
2024
Q3 		$13.2K Sell
1,421
-8,739
-86% -$63.3K ﹤0.01% 3533
2024
Q2 		$58.4K Buy
10,160
+9,766
+2,479% +$58.2K ﹤0.01% 2976
2024
Q1 		$2.64K Sell
394
-1,133
-74% -$6.29K ﹤0.01% 5004
2023
Q4 		$9.85K Sell
1,527
-3,394
-69% -$14.6K ﹤0.01% 4338
2023
Q3 		$24.6K Buy
4,921
+3,692
+300% +$28.5K ﹤0.01% 3191
2023
Q2 		$8.65K Sell
1,229
-1,135
-48% -$7.94K ﹤0.01% 4397
2023
Q1 		$15K Buy
2,364
+1,112
+89% +$7.28K ﹤0.01% 3781
2022
Q4 		$8K Sell
1,252
-2,435
-66% -$18.4K ﹤0.01% 4387
2022
Q3 		$31K Buy
3,687
+1,767
+92% +$22.7K ﹤0.01% 3574
2022
Q2 		$26K Buy
1,920
+1,026
+115% +$13.2K ﹤0.01% 3509
2022
Q1 		$14K Sell
894
-840
-48% -$11.5K ﹤0.01% 3884
2021
Q4 		$39K Buy
1,734
+913
+111% +$13.1K ﹤0.01% 2971
2021
Q3 		$11K Sell
821
-578
-41% -$6.4K ﹤0.01% 4218
2021
Q2 		$15K Sell
1,399
-568
-29% -$6.19K ﹤0.01% 4122
2021
Q1 		$26K Buy
1,967
+1,529
+349% +$25.1K ﹤0.01% 3678
2020
Q4 		$9K Buy
+438
New +$8.39K ﹤0.01% 4379

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Tower Research Capital (TRC)'s FHTX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Foghorn Therapeutics (FHTX) stake by 59% in Q1 2026, buying an estimated $6.71K and bringing the position to 3,295 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3653.

Tower Research Capital (TRC) first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $58.4K in Q2 2024. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Tower Research Capital (TRC) held 3,295 shares of Foghorn Therapeutics worth $15.8K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,222 Foghorn Therapeutics shares in Q1 2026, an estimated $6.71K.
  • Foghorn Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3653 holding.
  • Tower Research Capital (TRC) first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Foghorn Therapeutics position peaked at $58.4K in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.